Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Free Report) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 7,000 shares, a growth of 11.1% from the August 15th total of 6,300 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,300 shares, the days-to-cover ratio is currently 0.8 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, August 15th.
Check Out Our Latest Research Report on Armata Pharmaceuticals
Institutional Inflows and Outflows
Armata Pharmaceuticals Stock Performance
Armata Pharmaceuticals stock traded up $0.04 during midday trading on Wednesday, reaching $2.30. 809 shares of the company’s stock were exchanged, compared to its average volume of 13,588. The stock has a market capitalization of $83.21 million, a P/E ratio of -1.01 and a beta of 0.79. Armata Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $4.48.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Research analysts forecast that Armata Pharmaceuticals will post -1.02 earnings per share for the current year.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Further Reading
- Five stocks we like better than Armata Pharmaceuticals
- When to Sell a Stock for Profit or Loss
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- Investing In Preferred Stock vs. Common Stock
- Stocks to Take Advantage of Rising Gold Prices
- Do ETFs Pay Dividends? What You Need to Know
- Smartsheet Is a Smart Buy for Traders and Investors: Here’s Why
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.